| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
84 |
| Employees |
27 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-104 |
| Cash Flow (TTM) (Millions $) |
-26 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
Fusion Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing targeted alpha therapies for the treatment of cancer. The company uses novel approaches that combine targeted alpha therapeutics with radiation-guided drug delivery to specifically target cancer cells while sparing healthy tissues.
Fusion Pharmaceuticals utilizes its proprietary Fast-Clear linker technology platform to connect alpha-emitting isotopes with targeting molecules, such as antibodies or peptides. This approach allows them to deliver high doses of radiation directly to cancer cells, potentially enhancing the efficacy of therapy and minimizing side effects.
By developing innovative therapies, Fusion Pharmaceuticals aims to address critical unmet needs in oncology and provide safer and more effective treatment options for cancer patients. The company is actively advancing its pipeline of targeted alpha therapies, with various candidates in preclinical and clinical development stages.
Company Address: 270 Longwood Rd., S. Hamilton 0 ON
Company Phone Number: 799-0891 Stock Exchange / Ticker: NASDAQ FUSN
|
%
0.08% 